Head-to-head evidence

Beijing Biotech anti-CD19 CAR-T vs UTAA09

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

💬 Discuss in AI Terminal →

Systemic Lupus Erythematosus

Shared mechanism: CD19 · full Systemic Lupus Erythematosus pipeline

Beijing Biotech anti-CD19 CAR-T

Developed by Beijing Biotech

Phase 1/2 in Systemic Lupus ErythematosusCAR-T cell therapy

not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT07523542 (registry estimate)

Unlock with Research ↗

UTAA09

Developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1 in Systemic Lupus ErythematosusCAR-T cell therapy

Weak signal

NCT06417398 · Phase 1 · status unknown

This is an open-label, single-arm study with no control group and only 10 patients, and it has not yet reported any results, so there is no controlled evidence here yet.

Unlock with Research ↗

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Beijing Biotech anti-CD19 CAR-T's landscape · UTAA09's landscape